Definitive Healthcare Corp. (NASDAQ:DH) Receives Consensus Rating of “Hold” from Analysts

Definitive Healthcare Corp. (NASDAQ:DH) has earned a consensus rating of “Hold” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $4.7333.

DH has been the subject of several recent analyst reports. Robert W. Baird set a $4.00 price objective on Definitive Healthcare in a report on Friday, August 8th. Stifel Nicolaus increased their price objective on Definitive Healthcare from $5.00 to $6.00 and gave the company a “buy” rating in a report on Friday, August 8th. The Goldman Sachs Group increased their price objective on Definitive Healthcare from $3.00 to $3.40 and gave the company a “neutral” rating in a report on Monday, May 12th. BTIG Research downgraded Definitive Healthcare from a “buy” rating to a “neutral” rating in a report on Friday, May 9th. Finally, Wall Street Zen upgraded Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, June 21st.

Institutional Investors Weigh In On Definitive Healthcare

A number of large investors have recently added to or reduced their stakes in DH. Wells Fargo & Company MN raised its stake in Definitive Healthcare by 27.4% in the 4th quarter. Wells Fargo & Company MN now owns 31,297 shares of the company’s stock valued at $129,000 after acquiring an additional 6,736 shares during the period. Barclays PLC grew its holdings in Definitive Healthcare by 11.5% in the 4th quarter. Barclays PLC now owns 91,312 shares of the company’s stock valued at $376,000 after buying an additional 9,396 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Definitive Healthcare by 1.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,863,912 shares of the company’s stock valued at $7,661,000 after buying an additional 23,410 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Definitive Healthcare by 20.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,572 shares of the company’s stock valued at $85,000 after buying an additional 3,496 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Definitive Healthcare by 3.2% in the 4th quarter. Northern Trust Corp now owns 497,279 shares of the company’s stock valued at $2,044,000 after buying an additional 15,530 shares in the last quarter. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Trading Up 3.1%

NASDAQ:DH opened at $4.01 on Friday. Definitive Healthcare has a twelve month low of $2.15 and a twelve month high of $5.68. The company has a market cap of $573.99 million, a P/E ratio of -1.51 and a beta of 1.65. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.39. The business has a 50 day moving average price of $3.95 and a two-hundred day moving average price of $3.47.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.